Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


PatchXpress 7000A Automated Parallel Patch Clamp System

Product Description
The PatchXpress® 7000A Automated Parallel Patch Clamp System has revolutionized ion channel drug discovery. With over 13 independent peer reviewed scientific publications, the data quality from the PatchXpress 7000A System is considered to be equivalent to conventional patch clamp-or even better, since it eliminates potential operator bias.

The system's rapid compound addition rate (t=10-15 ms) enables the assay of rapidly desensitizing ligand-gated ion channels, such as the a-7 nicotinic acetylcholine receptor. The independent wash station with individual control for each assay well provides virtually unlimited washout of each recording chamber. This enables the removal of excess cells before the procedure, prevents cumulative desensitization of ligand-gated ion channels, and allows addition of multiple test compounds to the same cell if desired. The use of disposable pipette tips prevents any chance of cross contamination between compound additions, and the optional tip re-use function minimizes non-specific binding of compounds to the pipette tips.

The PatchXpress 7000A System has been successfully used on a large and steadily growing number of different cell types and ion channel classes. The highly configurable patch settings in combination with sophisticated monitoring of membrane parameters make it possible to adapt the experimental parameters using PatchXpress Commander to ideally suit a variety of targets. The system software with its intuitive and logical operation receives rave reviews by our customers and features all the functionality a dedicated researcher needs. The software is based on Clampex module in pCLAMP™ Software and will be familiar to every electrophysiologist that has ever used pCLAMP.
Product PatchXpress 7000A Automated Parallel Patch Clamp System
Company Molecular Devices Product Directory
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Molecular Devices Product Directory
1311 Orleans Drive Sunnyvale, CA 94089-11361 United States

Tel: 1-800-635-5577
Fax: 1-408-548-6439
Email: om@moldev.com



Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.

SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!